You are here

Database of section 19A approvals to import and supply medicines to address medicine shortages

22 April 2021

This database provides information on medicines not on the Australian Register of Therapeutic Goods (ARTG) that are approved for import and supply in Australia because:

  • there is a shortage of a medicine registered in Australia; and
  • the medicine is needed in the interest of public health.

The database holds information on approvals current on or after 21 Feburary 2018. Contact the TGA's Medicines Shortages Section for information on approvals that expired or lapsed before 21 Feburary 2018.

Consumers can use medicines accessed under section 19A until the medicines expire.

The 'Import and supply approved until' date applies to the approval holder importing and supplying the medicine.

The Medicines Shortages Information Initiative lists medicines that are unavailable or in short supply. If you are having difficulty obtaining a treatment that has been prescribed to you, talk to your doctor or pharmacist.

Section 19A approvals are granted for a specified period, which usually coincides with the period that the medicine on the ARTG is unavailable or in short supply. However, approval may lapse early if:

  • a decision has been made about whether or not to register the medicine in Australia
  • any of the specific criteria for approval no longer apply (for example, the registered medicine is no longer in short supply)
  • a condition of approval has been breached.

Section 19A approvals are subject to a number of conditions specified by the TGA including the following (though additional conditions can be imposed where the circumstances warrant it):

  • the approval applies only to the medicine specified in the approval
  • the approval is only for importation into and supply within Australia
  • the medicine is sourced from manufacturers with acceptable evidence of Good Manufacturing Practice (GMP)
  • a letter to health professionals who will be prescribing the medicine is usually required
  • the goods must be labelled with the name and address of the approval holder to ensure that adverse events can be reported.

Section 19A approvals

Displaying 1 - 4 of 4

Enter an approval holder, product name, active ingredient, indication or ARTG number.
Import and supply approved until: 30 June 2021
Section 19A approved medicine:

Sertraline 100mg film-coated tablets (Ranbaxy UK)


Medicine in short supply/unavailable:

  • APO-SERTRALINE sertraline (as hydrochloride) 100mg tablet blister pack - ARTG 213180
  • ELEVA 100 sertraline (as hydrochloride) 100 mg tablet blister pack - ARTG 95583
  • SERTRALINE SANDOZ sertraline 100mg (as hydrochloride) film coated tablet blister pack - ARTG 98698
  • SERTRA 100 sertraline (as hydrochloride) 100 mg tablet blister pack - ARTG 213181
  • SETRONA sertraline (as hydrochloride) 100 mg tablet blister pack - ARTG 116636
  • ZOLOFT sertraline (as hydrochloride) 100 mg tablet blister pack - ARTG 321602
  • SERTRALINE GENERICHEALTH sertraline 100mg (as hydrochloride) tablet blister pack - ARTG 124856

Section 19A approval holder: Barwon Pharma Pty Ltd ABN 93 169 715 066

Approval holder phone number: 0427 902 599

Indicated for the treatment of children (aged 6 years of age and older) and adolescents with obsessive compulsive disorder (OCD).

Indicated in adults for the treatment of:

  • Major depression
  • Obsessive compulsive disorder (OCD)
  • Panic disorder
  • Social phobia (social anxiety disorder) and the prevention of its relapse
  • Pre-menstrual dysphoric disorder (PMDD) as defined by DSM-IV criteria
Import and supply approved until: 30 June 2021
Section 19A approved medicine:

Sertraline 50mg film-coated tablets (Ranbaxy UK)


Medicine in short supply/unavailable:

  • APO-SERTRALINE sertraline (as hydrochloride) 50mg tablet blister pack - ARTG 213177
  • SETRONA sertraline (as hydrochloride) 50 mg tablet blister pack - ARTG 116623
  • SERTRALINE-STR sertraline (as hydrochloride) 50 mg tablet blister pack - ARTG 107067
  • SERTRALINE SANDOZ sertraline 50mg (as hydrochloride) film coated tablet blister pack - ARTG 98697
  • SERTRALINE GENERICHEALTH sertraline 50mg (as hydrochloride) tablet blister pack - ARTG 124855

Section 19A approval holder: Barwon Pharma Pty Ltd ABN 93 169 715 066

Approval holder phone number: 0427 902 599

Indicated for the treatment of children (aged 6 years of age and older) and adolescents with obsessive compulsive disorder (OCD).

Indicated in adults for the treatment of:

  • Major depression
  • Obsessive compulsive disorder (OCD)
  • Panic disorder
  • Social phobia (social anxiety disorder) and the prevention of its relapse
  • Pre-menstrual dysphoric disorder (PMDD) as defined by DSM-IV criteria
Import and supply approved until: 30 June 2021
Section 19A approved medicine:

Sertraline 100mg tablets, USP (Cipla)


Medicine in short supply/unavailable:

  • APO-SERTRALINE sertraline (as hydrochloride) 100 mg tablet blister pack - ARTG 213180
  • SERTRALINE SANDOZ sertraline (as hydrochloride) 100 mg flim coated tablet blister pack - ARTG 98698
  • ELEVA 100 sertraline (as hydrochloride) 100 mg tablet blister pack - ARTG 95583

Section 19A approval holder: Medsurge Healthcare Pty Ltd ABN 92 124 728 892

Approval holder phone number: 1300 788 261

Indicated for the treatment of children (aged 6 years of age and older) and adolescents with obsessive compulsive disorder (OCD).

Indicated in adults for the treatment of:

  • Major depression
  • Obsessive compulsive disorder (OCD)
  • Panic disorder
  • Social phobia (social anxiety disorder) and the prevention of its relapse
  • Pre-menstrual dysphoric disorder (PMDD) as defined by DSM-IV criteria
Import and supply approved until: 30 June 2021
Section 19A approved medicine:

Sertraline 50mg tablets, USP (Cipla)


Medicine in short supply/unavailable:

  • APO-SERTRALINE sertraline (as hydrochloride) 50 mg tablet blister pack - ARTG 213177

Section 19A approval holder: Medsurge Healthcare Pty Ltd ABN 92 124 728 892

Approval holder phone number: 1300 788 261

Indicated for the treatment of children (aged 6 years of age and older) and adolescents with obsessive compulsive disorder (OCD).

Indicated in adults for the treatment of:

  • Major depression
  • Obsessive compulsive disorder (OCD)
  • Panic disorder
  • Social phobia (social anxiety disorder) and the prevention of its relapse
  • Pre-menstrual dysphoric disorder (PMDD) as defined by DSM-IV criteria